Tesamorelin

TH9507 GHRH(1-44) Egrifta Analog (Research Grade)

Tesamorelin is a synthetic GHRH analog composed of the full 44-amino-acid sequence of human GHRH. Approved by the FDA for HIV-associated lipodystrophy; research-grade version is sold for animal and in vitro research only.

Purchase Options

Quantity

$108.00

Bundle & Save

1 Bottle

Certificate of Analysis

Full-panel third-party testing on every batch. 8× independent QC checks before any vial ships.

99.78%

Purity (HPLC-UV) · Identity Confirmed

Full panel passed

Tesamorelin · 10mg

Lot 261807 · Freedom Diagnostics
Reported Jul 24, 2026

View Certificate

8× Full QC Panel

Purity (HPLC) · Net Peptide Content · Identity (HPLC) · Fentanyl Screen · HPLC Conformity · Heavy Metals (ICP-MS) · Sterility (PCR) · Endotoxin (USP <85>)

All tests · Every batch

Compound Information

Technical specifications

What Is Tesamorelin?

Molecular Profile

Type	GHRH receptor agonist (full-length)
CAS Number	218949-48-5
Molecular Weight	5135.90 g/mol
Amino Acids	44

Stability Information

Storage Requirements

Protect from light

Store away from moisture

Reconstitute with sterile diluent

Lyophilized (powder) · −20°C · up to 2 years

Reconstituted · 2–8°C · up to 7 days

Sources & References

Peer-reviewed research

Annals of Internal Medicine

Effects of Tesamorelin, a Growth Hormone–Releasing Factor Analog, on Visceral Fat in HIV-Infected Patients

2010 · PMID: 20921541

Falutz J et al.

View Source

For Research Use Only

This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.